Inter-patient Variability in Clinical Efficacy of Metformin in Type 2 Diabetes Mellitus Patients in West Bengal, India
|Biswabandhu Bankura1, Madhusudan Das1, Arup Kumar Pattanayak1, Bidisha Adhikary1, Rana Bhattacharjee2, Soumik Goswami2, Subhankar Chowdhury2and Ajitesh Roy2*|
|1Department of Zoology, University of Calcutta, 35 Ballygunge Circular Road, Kolkata-700 019, West Bengal, India|
|2Department of Endocrinolgy, Institute of Post Graduate Medical Education & Research, 244 A J C Bose Road, Kolkata-700 020, West Bengal, India|
|*Corresponding Author :||Dr. Ajitesh Roy
Department of Endocrinolgy
Institute of Post Graduate
Medical Education & Research
J C Bose Road, Kolkata
West Bengal, India
E-mail: [email protected]
|Received January 08, 2016; Accepted February 10, 2016; Published February 17, 2016|
|Citation: Bankura B, Das M, Pattanayak AK, Adhikary B, Bhattacharjee R, et al. (2016) Inter-patient Variability in Clinical Efficacy of Metformin in Type 2 Diabetes Mellitus Patients in West Bengal, India. J Metabolic Synd 5:198. doi:10.4172/2167-0943.1000198|
|Copyright: © 2016 Bankura B, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.|
Background and objective: Metformin is often used as a first-line therapy for Type 2 diabetes mellitus (T2DM), but the glycemic response to metformin is variable in patients. Here, we aimed to assess the inter-patient variability in terms of glycemic response to metformin in the state of West Bengal, India.
Material and methods: We enrolled newly diagnosed treatment naïve 113 patients with T2DM. Patients were subjected to assay of glycated hemoglobin (HbA1c), fasting blood glucose (FBG), postprandial blood glucose (PP) and measurement of body mass index (BMI), waist circumstances (WC) before and after the end of 3 months of immediate release metformin (2000mg/day) therapy.
Results: Out of 113 patients, 111 (58 male and 53 female; average age 43.13 years) were provided with 3 months of metformin therapy. 102 individuals responded to metformin, but HbA1c levels of 9 patients did not improve after 3 months of drug therapy. Conclusions: In the present study, metformin lead to improvements in glycemic control in 92% of newly diagnosed T2DM patients but in 8% does not which is much less in this part of India.